These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8426494)

  • 81. Efficacy of monotherapy with low-density lipoprotein apheresis for severe renal disorder caused by cholesterol crystal embolization: A case report.
    Yoshida N; Shimozato S; Wada Y
    Ther Apher Dial; 2022 Oct; 26(5):1056-1057. PubMed ID: 35484938
    [No Abstract]   [Full Text] [Related]  

  • 82. [Reaction between low density lipoproteins and cultured fibroblasts in a case of familial hypercholesterolemia].
    Wehr H; Ciświcka-Sznajderman M; Abramowicz T; Korniszewski L; Naruszewicz M
    Pol Arch Med Wewn; 1982; 67(5-6):265-71. PubMed ID: 7177888
    [No Abstract]   [Full Text] [Related]  

  • 83. Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia.
    Kayikcioglu M; Tokgozoglu L; Tuncel OK; Pirildar S; Can L
    J Clin Lipidol; 2021; 15(2):381-382. PubMed ID: 34099193
    [No Abstract]   [Full Text] [Related]  

  • 84. Treatment methods for LDL apheresis.
    Bertrams A; Strout N
    J Clin Apher; 1994; 9(4):241. PubMed ID: 7759470
    [No Abstract]   [Full Text] [Related]  

  • 85. Low density lipoproteins inhibit endotoxin activation of monocytes.
    Weinstock C; Ullrich H; Hohe R; Berg A; Baumstark MW; Frey I; Northoff H; Flegel WA
    Arterioscler Thromb; 1992 Mar; 12(3):341-7. PubMed ID: 1547193
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Ellins EA; Watkins S; Rees DA; Datta DBN; Halcox JP
    Atherosclerosis; 2021 May; 325():121-123. PubMed ID: 33883085
    [No Abstract]   [Full Text] [Related]  

  • 87. Response to Duell et al.
    Tavori H; Giunzioni I; Linton MF; Fazio S
    Circ Res; 2014 Jun; 115(1):e5. PubMed ID: 24951770
    [No Abstract]   [Full Text] [Related]  

  • 88. Metabolic effects of liver replacement in homozygous familial hypercholesterolemia.
    Cienfuegos JA; Pardo F; Turrión VS; Ardaiz J; Mora NP; Escartín P; Garrido A; Barrios C; Cuervas-Mons V
    Transplant Proc; 1987 Oct; 19(5):3815-7. PubMed ID: 3313932
    [No Abstract]   [Full Text] [Related]  

  • 89. Managing familial hypercholesterolaemia.
    Jones JL; Lakasing E; Archontakis S
    Practitioner; 2009 Jun; 253(1719):28-31. PubMed ID: 19606612
    [No Abstract]   [Full Text] [Related]  

  • 90. Pregnancy in a homozygous familial hypercholesterolemic patient treated with long-term plasma exchange.
    Beigel Y; Hod M; Fuchs J; Lurie J; Friedman S; Green P; Merlob P; Melamed R; Ovadia J
    Am J Obstet Gynecol; 1990 Jan; 162(1):77-8. PubMed ID: 2301520
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Use of various extracorporeal methods of treatment in cardiology].
    Kukharchuk VV; Arabidze GG
    Kardiologiia; 1986 Oct; 26(10):7-11. PubMed ID: 3795710
    [No Abstract]   [Full Text] [Related]  

  • 92. [The treatment of familial hypercholesterolemia].
    Viener A; Brook GJ
    Harefuah; 1987 Apr; 112(8):402-5. PubMed ID: 3315897
    [No Abstract]   [Full Text] [Related]  

  • 93. Successful plasmapheresis in a 4-year-old child with homozygous familial hypercholesterolemia.
    Witztum JL; Williams JC; Ostlund R; Sherman L; Siccard G; Schonfeld G
    J Pediatr; 1980 Oct; 97(4):615-8. PubMed ID: 6775065
    [No Abstract]   [Full Text] [Related]  

  • 94. Changes in the metabolism of modified and unmodified low-density lipoproteins during the maturation of cultured blood monocyte-macrophages from normal and homozygous familial hypercholesterolaemic subjects.
    Knight BL; Soutar AK
    Eur J Biochem; 1982 Jul; 125(2):407-13. PubMed ID: 7117242
    [No Abstract]   [Full Text] [Related]  

  • 95. [A case report of homozygous familial hypercholesterolemia (author's transl)].
    Abe R; Maruhama Y; Okuguchi F; Oikawa S; Kakizaki M; Suzuki H; Goto Y
    Nihon Naika Gakkai Zasshi; 1980 Nov; 69(11):1452-7. PubMed ID: 7240891
    [No Abstract]   [Full Text] [Related]  

  • 96. Plasma exchange in two "receptor negative" homozygotes for autosomal, dominant hypercholesterolemia.
    Maartmann-Moe K; Stenerud O; Fagerhol MK; Solberg LA; Torsvik H; Leren P
    J Oslo City Hosp; 1982; 32(5-6):55-65. PubMed ID: 6284897
    [No Abstract]   [Full Text] [Related]  

  • 97. Introducing Personalized Medicine Into Pediatric Homozygous Familial Hypercholesterolemia Care.
    Gidding SS; Hegele RA
    Arterioscler Thromb Vasc Biol; 2022 Dec; 42(12):1458-1460. PubMed ID: 36325896
    [No Abstract]   [Full Text] [Related]  

  • 98. Barriers to the Implementation of Lipoprotein Apheresis in Canada.
    Filler G; Lee M; Hegele RA
    Can J Cardiol; 2017 Mar; 33(3):409-411. PubMed ID: 28232020
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [The enhanced activity of chymotrypsin-like proteinases in the blood plasma of patients with hereditary hypercholesterolemia and the means for its correction].
    Ogloblina OG; Alidzhanova KhG; Konovalov GA; Kukharchuk VV
    Ter Arkh; 1992; 64(9):58-60. PubMed ID: 1481156
    [No Abstract]   [Full Text] [Related]  

  • 100. Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia.
    Kayikcioglu M; Tokgozoglu L; Tuncel OK; Pirildar S; Can L
    J Clin Lipidol; 2020; 14(6):751-755. PubMed ID: 32988799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.